Welcome to our dedicated page for Benitec Biopharm SEC filings (Ticker: BNTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Benitec Biopharma Inc.’s SEC filings document a Nasdaq-listed clinical-stage biotechnology company developing genetic medicines, including the BB-301 program for OPMD-related dysphagia. Its reports and current filings cover operating and financial results, clinical-development updates, Regulation FD disclosures, and capital-structure information for its common stock.
The company’s proxy and governance filings describe annual meeting matters, board composition, director compensation, equity incentive arrangements, and related corporate-governance disclosures. Form 8-K filings also record material events such as financial-result releases, operational updates, clinical-study disclosures, and director appointments.